Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
WELLS DAVID B reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director David B. Wells received a grant of 957 restricted stock units as part of his 2026 first-quarter board compensation. The RSUs were issued in lieu of $22,000 of cash retainer and committee fees, using a grant price of $22.98 per unit. Each RSU represents a contingent right to receive one share of Class A common stock and will vest in full on the company’s next quarterly vesting date. Following this compensation grant, Wells holds 957 RSUs directly.
Hims & Hers Health, Inc. issued $402.5 million principal amount of 0.00% Convertible Senior Notes due 2032 in a private offering to qualified institutional buyers. The notes pay no regular interest, mature on June 1, 2032, and can be converted into cash, Class A common stock, or a combination.
The initial conversion rate is 33.8590 shares per $1,000 principal amount, implying an initial conversion price of about $29.53 per share. A maximum of 18,057,397 shares may be issued on conversion under the initial maximum conversion rate, subject to customary anti‑dilution adjustments.
The company also entered into capped call transactions covering the shares underlying the notes, with an initial cap price of approximately $50.15 per share and a cost of about $36.7 million. These capped calls are designed to reduce potential dilution or offset cash payments above principal upon conversion, subject to the cap.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A common stock. He exercised stock options to acquire 7,950 shares at $5.01 per share and sold 7,950 shares at an average price of $23.6372 per share.
Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes that the stock option exercises and sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025, and that the stock options were fully vested and exercisable.
Hims & Hers Health, Inc. is raising capital through a private offering of 0.00% convertible senior notes due 2032. The company priced $350 million in aggregate principal amount, upsized from a proposed $300 million, with an option for an additional $52.5 million.
Hims & Hers expects net proceeds of about $338.5 million, to support international expansion, including its proposed Eucalyptus acquisition, and to invest in technology, fulfillment infrastructure, and AI-driven platform capabilities. A portion, including approximately $32.0 million, will fund capped call transactions intended to limit dilution from note conversions.
Hims & Hers Health, Inc. Schedule 13G discloses beneficial ownership by four affiliated broker-dealer entities reporting collective shared voting and dispositive power over 14,502,395 shares, representing 6.5% of the Class A common stock as of March 31, 2026.
The filing states that Susquehanna Investment Group reports options to buy 560,500 shares and Susquehanna Securities, LLC reports options to buy 12,290,400 shares. The issuer had 222,326,117 shares outstanding as of March 31, 2026 per the company's Form 10-Q filed May 11, 2026.
Hims & Hers Health, Inc. Schedule 13G/A amendment reports that Capital World Investors is beneficially owned of 2 shares of Common Stock, representing 0.0% of the 219,561,143 shares believed to be outstanding. The filing is signed by an authorized representative on 05/13/2026.
Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up from $586.0 million a year earlier, but shifted from profit to a net loss of $92.1 million, or $(0.40) per diluted share, versus diluted EPS of $0.20 in Q1 2025.
Results were pressured by $33.5 million in non-recurring restructuring and related charges tied to a U.S. weight-loss offering shift and $17.6 million of fair value losses on liabilities plus $9.7 million on equity securities. The company still generated $89.4 million in operating cash flow and ended the quarter with $222.3 million in cash and $528.6 million in short-term investments.
Hims & Hers closed the $153.0 million YourBio acquisition, continued integrating prior Medici and Zava deals, and outlined a planned Eucalyptus purchase for up to $1.15 billion. It also carried $1.0 billion of 0% convertible notes due 2030 and recorded a $15.0 million accrual related to an FTC ROSCA investigation.
Hims & Hers Health, Inc. reported first quarter 2026 revenue of $608.1 million, up 4% from $586.0 million a year earlier, driven by nearly 2.6 million subscribers, an increase of 9%. Rest of world revenue rose sharply while U.S. revenue declined 8%.
Profitability deteriorated as gross margin fell to 65% from 73%. The company swung to a net loss of $92.1 million from net income of $49.5 million, and Adjusted EBITDA declined to $44.3 million from $91.1 million, with margin compressing to 7%.
Management highlighted a strategic pivot expanding branded GLP-1 offerings and recorded restructuring and legal settlement charges. Despite near-term margin pressure, the company generated $53.0 million in Free Cash Flow and raised full-year 2026 guidance to $2.8–$3.0 billion in revenue and $275–$350 million in Adjusted EBITDA, targeting a 10–12% margin.
Hims & Hers Health, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on three items: electing nine directors, ratifying KPMG LLP as auditor for 2026, and approving executive pay on an advisory basis. The Board unanimously recommends voting “FOR” all proposals.
The proxy highlights strong 2025 performance, with revenue of $2.35 billion, up 59% year over year, and more than 2.5 million subscribers, up 13%. Net income was $128.4 million, compared with $126.0 million in 2024, while Adjusted EBITDA reached $318.0 million. Operating cash flow was $300.0 million and Free Cash Flow was $57.4 million.
The company is a NYSE “controlled company” because CEO Andrew Dudum, through Class A and high-vote Class V shares, holds over 50% of voting power and approximately 87.7% of total voting power. Despite this status, a majority of directors are independent, and all audit and compensation committee members are independent. The proxy also describes board committee structures, risk oversight, diversity metrics, and a pay program that is heavily equity-based and performance-linked, with executives earning about 94% of target 2025 bonuses based on revenue and Adjusted EBITDA results.